(Updated - August 30, 2017 7:37 AM EDT)


(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Trading Halts

Otonomy (OTIC) PT Lowered to $9 at Cowen Amid Otividex Failure; Dramatic And Fast Changes NeededAugust 30, 2017 10:44 AM JPMorgan Downgrades Otonomy (OTIC ) to NeutralAugust 30, 2017 9:42 AM Otonomy (OTIC) to Resume Trading at 7:30 AM ETAugust 30, 2017 7:25 AM Otonomy (OTIC) Says AVERTS-1 Phase 3 Trial for OTIVIDEX Missed Primary EndpointAugust 30, 2017 7:02 AM Form 8-K OTONOMY, INC. For: Aug 30August 30, 2017 7:01 AM Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's DiseaseAugust 30, 2017 7:00 AM Otonomy (OTIC) Halted, News PendingAugust 30, 2017 6:57 AM